Patents by Inventor Florian Grupp

Florian Grupp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD
    Patent number: 10094826
    Abstract: Described is a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, including measuring the concentration of anti-CCP and anti-PIK 3CD and correlating the concentrations determined to the absence or presence of RA. Also disclosed is the use of a marker panel including anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method. Also described is the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Stefan Weiser, Johann Karl, Ursula Kunert, Florian Grupp
  • METHOD OF ASSESSING RHEUMATOID ARTHRITIS BY MEASURING ANTI-CCP AND ANTI-PIK3CD
    Publication number: 20180003710
    Abstract: The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, comprising measuring the concentration of anti-CCP and anti-PIK3CD and correlating the concentrations determined to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method of the invention. Further the invention relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).
    Type: Application
    Filed: August 10, 2017
    Publication date: January 4, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Stefan Weiser, Johann Karl, Ursula Kunert, Florian Grupp